Premium
Calycosin enhances the bactericidal efficacy of polymyxin B by inhibiting MCR‐1 in vitro
Author(s) -
Liu X.,
Sun X.,
Deng X.,
Lv X.,
Wang J.
Publication year - 2020
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/jam.14635
Subject(s) - calycosin , polymyxin b , polymyxin , cytotoxicity , microbiology and biotechnology , minimum inhibitory concentration , chemistry , in vitro , pharmacology , biology , biochemistry , antibiotics , daidzein , formononetin , genistein , endocrinology
Aim To examine the synergistic effect of calycosin combined with polymyxin B against various mcr‐1 ‐positive bacterial strains. Methods and Results In this study, we found a potential inhibitor of MCR‐1, calycosin, that could significantly restore the antibacterial activity of polymyxin B. The synergistic effect of calycosin combined with polymyxin B against various mcr‐1 ‐positive bacterial strains was confirmed by checkerboard minimum inhibitory concentration assays, time‐kill curve assays and disk diffusion assays. The fractional inhibitory concentration indexes ranged from 0·15 ± 0·03 to 0·28 ± 0·05, and the zones of inhibition increased from 13·33 ± 0·47 to 17·67 ± 0·47 mm with the combined therapy of calycosin and polymyxin B. In addition, the combined therapy significantly reduced the number of bacteria in the medium. However, at the concentrations required for the synergistic effect with polymyxin B, calycosin alone showed no effect on bacterial growth or MCR‐1 production. Calycosin treatment exhibited no cytotoxicity to HeLa cells or A549 cells at calycosin concentrations below 32 µg ml −1 . Conclusions Therefore, our results suggested that calycosin could be used as a potential MCR‐1 inhibitor to restore the bactericidal effect of polymyxin B without affecting bacterial viability or existing cytotoxicity. Significance and Impact of the Study The synergistic effect of calycosin combined with polymyxin B against various mcr‐1 ‐positive bacterial strains paves the way for future pharmaceutical applications of calycosin in fighting mcr‐1 ‐positive bacterial infections.